Clene (CLNN) Competitors

$7.05 +0.55 (+8.46%)

Closing price 04:00 PM Eastern

Extended Trading

$6.84 -0.22 (-3.05%)

As of 05:37 PM Eastern

CLNN vs. CCCC, EDIT, ELDN, FHTX, and LENZ

Should you buy Clene stock or one of its competitors? MarketBeat compares Clene with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Clene include C4 Therapeutics (CCCC), Editas Medicine (EDIT), Eledon Pharmaceuticals (ELDN), Foghorn Therapeutics (FHTX), and LENZ Therapeutics (LENZ). These companies are all part of the "pharmaceutical products" industry.

How does Clene compare to C4 Therapeutics?

C4 Therapeutics (NASDAQ:CCCC) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

C4 Therapeutics has a beta of 2.77, suggesting that its stock price is 177% more volatile than the broader market. Comparatively, Clene has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

Clene has lower revenue, but higher earnings than C4 Therapeutics. Clene is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.95M	11.13	-$104.99M	-$1.36	N/A
Clene	$200K	415.25	-$26.17M	-$2.60	N/A

In the previous week, Clene had 8 more articles in the media than C4 Therapeutics. MarketBeat recorded 12 mentions for Clene and 4 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 0.78 beat Clene's score of 0.19 indicating that C4 Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Clene	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

C4 Therapeutics currently has a consensus price target of $7.75, suggesting a potential upside of 113.50%. Clene has a consensus price target of $33.25, suggesting a potential upside of 371.63%. Given Clene's stronger consensus rating and higher probable upside, analysts clearly believe Clene is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Clene	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

C4 Therapeutics has a net margin of -297.76% compared to Clene's net margin of -13,086.50%. Clene's return on equity of 0.00% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-297.76%	-53.23%	-33.81%
Clene	-13,086.50%	N/A	-135.77%

78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 5.6% of C4 Therapeutics shares are owned by company insiders. Comparatively, 28.3% of Clene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Clene beats C4 Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Clene compare to Editas Medicine?

Clene (NASDAQ:CLNN) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Clene has higher earnings, but lower revenue than Editas Medicine. Clene is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$200K	415.25	-$26.17M	-$2.60	N/A
Editas Medicine	$38.69M	7.21	-$160.06M	-$1.23	N/A

Clene has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market.

Editas Medicine has a net margin of -281.59% compared to Clene's net margin of -13,086.50%. Clene's return on equity of 0.00% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-13,086.50%	N/A	-135.77%
Editas Medicine	-281.59%	-677.39%	-58.25%

Clene currently has a consensus price target of $33.25, suggesting a potential upside of 371.63%. Editas Medicine has a consensus price target of $5.40, suggesting a potential upside of 89.47%. Given Clene's stronger consensus rating and higher probable upside, equities research analysts plainly believe Clene is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Clene had 4 more articles in the media than Editas Medicine. MarketBeat recorded 12 mentions for Clene and 8 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.22 beat Clene's score of 0.19 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Clene	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Editas Medicine	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

23.3% of Clene shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 28.3% of Clene shares are held by insiders. Comparatively, 3.1% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Editas Medicine beats Clene on 8 of the 15 factors compared between the two stocks.

How does Clene compare to Eledon Pharmaceuticals?

Clene (NASDAQ:CLNN) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

Clene currently has a consensus price target of $33.25, indicating a potential upside of 371.63%. Eledon Pharmaceuticals has a consensus price target of $9.67, indicating a potential upside of 144.73%. Given Clene's stronger consensus rating and higher probable upside, equities research analysts clearly believe Clene is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Clene had 8 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 12 mentions for Clene and 4 mentions for Eledon Pharmaceuticals. Clene's average media sentiment score of 0.19 beat Eledon Pharmaceuticals' score of -0.28 indicating that Clene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Clene	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eledon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Clene has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

Clene has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$200K	415.25	-$26.17M	-$2.60	N/A
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.52	N/A

Eledon Pharmaceuticals has a net margin of 0.00% compared to Clene's net margin of -13,086.50%. Clene's return on equity of 0.00% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-13,086.50%	N/A	-135.77%
Eledon Pharmaceuticals	N/A	-85.61%	-31.93%

23.3% of Clene shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 28.3% of Clene shares are held by insiders. Comparatively, 12.3% of Eledon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Clene beats Eledon Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Clene compare to Foghorn Therapeutics?

Foghorn Therapeutics (NASDAQ:FHTX) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Foghorn Therapeutics presently has a consensus price target of $11.13, indicating a potential upside of 175.37%. Clene has a consensus price target of $33.25, indicating a potential upside of 371.63%. Given Clene's higher probable upside, analysts clearly believe Clene is more favorable than Foghorn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Clene	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Foghorn Therapeutics has a beta of 2.97, meaning that its stock price is 197% more volatile than the broader market. Comparatively, Clene has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market.

Clene has lower revenue, but higher earnings than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foghorn Therapeutics	$30.91M	7.67	-$74.28M	-$1.16	N/A
Clene	$200K	415.25	-$26.17M	-$2.60	N/A

Foghorn Therapeutics has a net margin of -266.88% compared to Clene's net margin of -13,086.50%.

Company	Net Margins	Return on Equity	Return on Assets
Foghorn Therapeutics	-266.88%	N/A	-35.38%
Clene	-13,086.50%	N/A	-135.77%

In the previous week, Clene had 3 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 12 mentions for Clene and 9 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.41 beat Clene's score of 0.19 indicating that Foghorn Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Clene	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

61.6% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 7.6% of Foghorn Therapeutics shares are owned by company insiders. Comparatively, 28.3% of Clene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Foghorn Therapeutics beats Clene on 10 of the 16 factors compared between the two stocks.

How does Clene compare to LENZ Therapeutics?

Clene (NASDAQ:CLNN) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

In the previous week, LENZ Therapeutics had 7 more articles in the media than Clene. MarketBeat recorded 19 mentions for LENZ Therapeutics and 12 mentions for Clene. LENZ Therapeutics' average media sentiment score of 0.24 beat Clene's score of 0.19 indicating that LENZ Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Clene	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LENZ Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Clene has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

Clene has higher earnings, but lower revenue than LENZ Therapeutics. Clene is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$200K	415.25	-$26.17M	-$2.60	N/A
LENZ Therapeutics	$19.09M	11.97	-$82.13M	-$3.60	N/A

23.3% of Clene shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 28.3% of Clene shares are owned by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

LENZ Therapeutics has a net margin of -519.30% compared to Clene's net margin of -13,086.50%. Clene's return on equity of 0.00% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-13,086.50%	N/A	-135.77%
LENZ Therapeutics	-519.30%	-46.82%	-43.32%

Clene currently has a consensus target price of $33.25, indicating a potential upside of 371.63%. LENZ Therapeutics has a consensus target price of $29.80, indicating a potential upside of 308.78%. Given Clene's stronger consensus rating and higher probable upside, analysts plainly believe Clene is more favorable than LENZ Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Clene beats LENZ Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Clene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLNN vs. The Competition

Export

Metric	Clene	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$83.05M	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-2.71	18.81	20.87	25.58
Price / Sales	415.25	181.67	521.63	63.56
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	-4.35	6.74	9.86	6.70
Net Income	-$26.17M	$24.11M	$3.55B	$333.77M
7 Day Performance	-4.60%	0.07%	-0.32%	0.45%
1 Month Performance	5.54%	0.84%	1.34%	4.06%
1 Year Performance	165.04%	78.10%	41.03%	36.21%

Clene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLNN Clene	3.049 of 5 stars	$7.05 +8.5%	$33.25 +371.6%	+146.2%	$83.05M	$200K	N/A	100	News Coverage Earnings Report Insider Trade Gap Down
CCCC C4 Therapeutics	2.0588 of 5 stars	$3.04 +4.1%	$7.75 +154.9%	+145.3%	$284.93M	$35.95M	N/A	150	Earnings Report
EDIT Editas Medicine	3.5376 of 5 stars	$3.00 +3.4%	$5.30 +76.7%	+93.3%	$283.93M	$40.52M	N/A	230
ELDN Eledon Pharmaceuticals	2.0127 of 5 stars	$3.78 +2.4%	$9.67 +155.7%	+33.8%	$279.89M	N/A	N/A	10
FHTX Foghorn Therapeutics	2.8813 of 5 stars	$4.68 -1.7%	$11.13 +137.7%	-3.7%	$279.48M	$30.91M	N/A	120	Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLNN) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Clene (CLNN) Competitors

CLNN vs. CCCC, EDIT, ELDN, FHTX, and LENZ

How does Clene compare to C4 Therapeutics?

Summary

How does Clene compare to Editas Medicine?

Summary

How does Clene compare to Eledon Pharmaceuticals?

Summary

How does Clene compare to Foghorn Therapeutics?

Summary

How does Clene compare to LENZ Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLNN vs. The Competition

Clene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Clene (CLNN) Competitors

CLNN vs. CCCC, EDIT, ELDN, FHTX, and LENZ

How does Clene compare to C4 Therapeutics?

Which has more volatility & risk, CCCC or CLNN?

Which has higher valuation & earnings, CCCC or CLNN?

Does the media refer more to CCCC or CLNN?

Do analysts prefer CCCC or CLNN?

Is CCCC or CLNN more profitable?

Do institutionals & insiders have more ownership in CCCC or CLNN?

Summary

How does Clene compare to Editas Medicine?

Which has better earnings & valuation, CLNN or EDIT?

Which has more volatility & risk, CLNN or EDIT?

Is CLNN or EDIT more profitable?

Do analysts rate CLNN or EDIT?

Does the media prefer CLNN or EDIT?

Do insiders & institutionals have more ownership in CLNN or EDIT?

Summary

How does Clene compare to Eledon Pharmaceuticals?

Do analysts prefer CLNN or ELDN?

Does the media favor CLNN or ELDN?

Which has more risk & volatility, CLNN or ELDN?

Which has stronger earnings and valuation, CLNN or ELDN?

Is CLNN or ELDN more profitable?

Do insiders & institutionals hold more shares of CLNN or ELDN?

Summary

How does Clene compare to Foghorn Therapeutics?

Do analysts prefer FHTX or CLNN?

Which has more volatility & risk, FHTX or CLNN?

Which has better earnings and valuation, FHTX or CLNN?

Is FHTX or CLNN more profitable?

Does the media refer more to FHTX or CLNN?

Do insiders and institutionals believe in FHTX or CLNN?

Summary

How does Clene compare to LENZ Therapeutics?

Does the media prefer CLNN or LENZ?

Which has more volatility & risk, CLNN or LENZ?

Which has stronger earnings & valuation, CLNN or LENZ?

Do institutionals and insiders believe in CLNN or LENZ?

Is CLNN or LENZ more profitable?

Do analysts prefer CLNN or LENZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLNN vs. The Competition

Clene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools